AML Hub

⭐AML Hub spotlight: Findings from the cAMeLot-1 trial of bleximenib⭐ @DrEmmaSearle, @TheChristieNHS, shared findings at #ASH24 from the ongoing phase I/II cAMeLot-1 trial of bleximenib in patients with R/R KMT2Ar or NPM1m acute leukemia. #AMLsm #leusm #MedEd

Did you know you can filter content on the AML Hub website depending on your specific interests – whether that is by AML type, therapeutics, trials, or congresses? 👉 loom.ly/Ig9Q4z4 #amlsm #leusm #MedEd

📝 Data from the phase Ib/II KOMET-001 trial, presented by Amir Fathi at #EHA2025, show that ziftomenib was well tolerated in patients with relapsed/refractory NPM1m AML, consistent with previous findings. More news: aml-hub.com #AMLsm #leusm #MedNews #MedEd

🚨 News 🚨 ICT01, a humanized anti-BTN3A monoclonal antibody, has been granted orphan drug designation by @EMA_News for the treatment of AML. Read more: loom.ly/CIAWAwk #AMLsm #leusm #MedNews #MedEd

New publication 📝 In the phase Ib/II KOMET-001 trial of ziftomenib in patients with relapsed/refractory NPM1m AML, presented by Amir Fathi at #EHA2025, the phase II primary endpoint was met (CR/CRh rate, 23%). Learn more: loom.ly/eS_YBHE #AMLsm #leusm #MedNews #MedEd

📝 A prospective validation of the HCT-FS in patients undergoing allo-HSCT presented by Maria Queralt Salas at #EHA2025 confirms frailty as a prognostic indicator of 2-year OS and 2-year NRM. More news: aml-hub.com #AMLsm #leusm #MedNews #MedEd

🚨 News 🚨 @US_FDA has granted orphan drug designation to ICT01, a humanized anti-BTN3A monoclonal antibody, for the treatment of AML. Read more: loom.ly/3tc3F8w #AMLsm #leusm #MedNews #MedEd

New publication 📝 A prospective analysis presented by Maria Queralt Salas at #EHA2025 validates the HCT-FS as a reliable tool for stratifying adult candidates for allo-HSCT into fit, pre-frail, and frail categories. Learn more: loom.ly/iOZIwzs #AMLsm #leusm #MedNews…

How important to you is the turnaround time for genetic testing in guiding your initial treatment decisions? A. A fast turnaround time is critical (2–5 days) B. Will wait up to 10–14 days for NGS results C. Will wait up to 3 weeks for comprehensive assessment D. Begin…

📝 Updated data from the KOMET-007 trial, presented by Harry Erba at #EHA2025, show that ziftomenib with intensive induction therapy was well tolerated in patients with newly diagnosed NPM1m or KMT2Ar AML. More news: aml-hub.com #AMLsm #leusm #MedNews #MedEd

New data 📝 Updated results from the phase I KOMET-007 trial, presented by Harry Erba at #EHA2025, show robust clinical activity of ziftomenib with intensive induction chemotherapy in ND NPM1m and KMT2Ar AML. Learn more: loom.ly/hEm8a1A #AMLsm #leusm #MedNews #MedEd

🚨 News 🚨 @US_FDA has accepted the supplemental new drug application for decitabine + cedazuridine in combination with venetoclax for adults with newly diagnosed AML, with an assigned PDUFA target action date of Feb 25, 2026. Read more: loom.ly/25uMS5o #AMLsm #leusm…

🚨Catch up on the latest developments in real-world studies and risk stratification of acute myeloid leukemia from #EHA2025, with social media coverage from the AML Hub. Read more: loom.ly/aKb7W9M #AMLsm #leusm #MedNews #MedEd

📝 A new study published in @BMTjournal indicates that common barriers to HSCT in patients with TP53m AML include infection, concurrent other cancer, and relapse within <3 months post-remission. More news: aml-hub.com #AMLsm #leusm #MedEd

New publication📝 A retrospective analysis of barriers to HSCT and outcomes post-HSCT in patients with TP53m AML published in @BMTjournal found favorable outcomes post-HSCT regardless of pre-HSCT OR, cCR, or MRD negativity. Learn more: loom.ly/GaOnopc #AMLsm #leusm…

🎧 New podcast! Listen to @CharlieCraddock, Queen Elizabeth Hospital Birmingham, UK, sharing the closing remarks from the @Know_AML HCP–patient webinar, titled ‘Mutation testing in AML: What you need to know’. Listen: loom.ly/-Z5suvQ Watch: loom.ly/yY_OLqg…

To conclude the @Know_AML HCP-patient webinar, titled ‘Mutation testing in AML: What you need to know’, the faculty shared their closing remarks and addressed questions from the audience. Watch the full video here: loom.ly/yY_OLqg #KnowAML #AMLsm #leusm

Thank you to our funders, who make it possible for us to deliver the AML Hub. • Daiichi Sankyo • Hippocrate Conference Institute, an association of the Servier Group • Johnson & Johnson • Kura Oncology • Syndax #leusm

🚨Catch up on the latest developments in HSCT for the treatment of acute myeloid leukemia from #EHA2025, with social media coverage from the AML Hub. Read more: loom.ly/pTTS1I4 #AMLsm #leusm #MedNews #MedEd

📝 A new study published in @AjHematology by @jayastuMD et al. found that in venetoclax-treated genomic secondary AML, TP53 mutations and adverse cytogenetics were linked to higher mortality. ELN 2024 risk categories added further prognostic value. More news:…

New publication 📝 A retrospective analysis published in @AjHematology by @jayastuMD et al. reports similar OS and RFS in clinical secondary AML and genomic secondary AML – both significantly shorter than in de novo AML. Outcomes with venetoclax vary by genomic subtype. Learn…